Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1938-1942, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guldager, B.
Right arrow Articles by Grandjean, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guldager, B.
Right arrow Articles by Grandjean, P.

Clinical Chemistry, Vol 42, 1938-1942, Copyright © 1996 by American Association for Clinical Chemistry

Metal excretion and magnesium retention in patients with intermittent claudication treated with intravenous disodium EDTA

B Guldager, PJ Jorgensen and P Grandjean
Department of Surgery, Hillerod Hospital, Denmark.

Sixty patients with intermittent claudication participated in a double- blind placebo-controlled trial of 20 courses of intravenous chelation therapy with 3 g of disodium EDTA vs placebo during 5-9 weeks. After the first infusion, the 24-h urinary excretion of lead and zinc was approximately 25-fold higher in the EDTA-treated group; relative differences for copper and calcium were smaller. Urinary magnesium excretion in the EDTA-treated group was one-third less than in the control group. After the treatment period, the blood lead concentration had decreased by approximately 73% and the serum zinc concentration by approximately 34%; other changes in blood concentrations were negligible. The loss of essential minerals and the possible redistribution of lead in the body may constitute a disadvantage that should be taken into account in repeated intravenous EDTA treatment.


The following articles in journals at HighWire Press have cited this article:


Home page
 VASC ENDOVASCULAR SURGHome page
K. Casey, B. H. Tonnessen, W. C. Sternbergh III, and S. R. Money
Medical Management of Intermittent Claudication
Vascular and Endovascular Surgery, September 1, 2004; 38(5): 391 - 399.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.